223 related articles for article (PubMed ID: 30784672)
1. Cardiac Magnetic Resonance and Cardio-Oncology: Does T
Yu AF; Chan AT; Steingart RM
J Am Coll Cardiol; 2019 Feb; 73(7):792-794. PubMed ID: 30784672
[No Abstract] [Full Text] [Related]
2. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.
Galán-Arriola C; Lobo M; Vílchez-Tschischke JP; López GJ; de Molina-Iracheta A; Pérez-Martínez C; Agüero J; Fernández-Jiménez R; Martín-García A; Oliver E; Villena-Gutierrez R; Pizarro G; Sánchez PL; Fuster V; Sánchez-González J; Ibanez B
J Am Coll Cardiol; 2019 Feb; 73(7):779-791. PubMed ID: 30784671
[TBL] [Abstract][Full Text] [Related]
3. Coronary microcirculation damage in anthracycline cardiotoxicity.
Galán-Arriola C; Vílchez-Tschischke JP; Lobo M; López GJ; de Molina-Iracheta A; Pérez-Martínez C; Villena-Gutiérrez R; Macías Á; Díaz-Rengifo IA; Oliver E; Fuster V; Sánchez-González J; Ibanez B
Cardiovasc Res; 2022 Jan; 118(2):531-541. PubMed ID: 33605403
[TBL] [Abstract][Full Text] [Related]
4. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
5. [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
Vasyuk YA; Shkolnik EL; Nesterov VV; Shkolnik LD; Varlan GV
Kardiologiia; 2016 Dec; 56(12):72-79. PubMed ID: 28290807
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging.
Farhad H; Staziaki PV; Addison D; Coelho-Filho OR; Shah RV; Mitchell RN; Szilveszter B; Abbasi SA; Kwong RY; Scherrer-Crosbie M; Hoffmann U; Jerosch-Herold M; Neilan TG
Circ Cardiovasc Imaging; 2016 Dec; 9(12):. PubMed ID: 27923796
[TBL] [Abstract][Full Text] [Related]
8. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
10. Sexual dimorphism in doxorubicin cardiotoxicity: two sides of a complex coin.
Costa A; Ameri P
Am J Physiol Heart Circ Physiol; 2023 Nov; 325(5):H949-H951. PubMed ID: 37712921
[No Abstract] [Full Text] [Related]
11. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
13. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
14. Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?
Bernstein D
Circ Res; 2018 Jan; 122(2):188-190. PubMed ID: 29348242
[No Abstract] [Full Text] [Related]
15. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study.
Skitch A; Mital S; Mertens L; Liu P; Kantor P; Grosse-Wortmann L; Manlhiot C; Greenberg M; Nathan PC
BMC Cancer; 2017 Aug; 17(1):519. PubMed ID: 28774277
[TBL] [Abstract][Full Text] [Related]
16. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
Salvatorelli E; Menna P; Minotti G
Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550
[No Abstract] [Full Text] [Related]
17. Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.
Meiners B; Shenoy C; Zordoky BN
Biol Sex Differ; 2018 Aug; 9(1):38. PubMed ID: 30157941
[TBL] [Abstract][Full Text] [Related]
18. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
19. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
20. Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?".
Lipshultz SE
Circ Res; 2018 Mar; 122(7):e62-e63. PubMed ID: 29599279
[No Abstract] [Full Text] [Related]
[Next] [New Search]
